ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 957-962

  Mahalingam, Marthandan ^a   Arvind, Ramanathan ^a   Ida, Hiroyuki ^b   Murugan, Avaniyapuram Kannan ^a   Yamaguchi, Masamitsu ^b   Tsuchida, Nobuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Common docking domain; Extracellular signal regulated kinase 2; Mitogen activated protein kinase; MKP; Sevenmaker; Transformation

Indexed keywords

AGAR; AMINO ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DROSOPHILA; EYE DEVELOPMENT; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; TRANSGENIC ANIMAL; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BALB 3T3 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DROSOPHILA; DUAL SPECIFICITY PHOSPHATASE 1; EYE ABNORMALITIES; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 54949130145     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000096     Document Type: Article

References (34)

1. Nishida E and Gotoh Y: The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 18: 128-131, 1993.
2. Turjanski AG, Vaqué JP and Gutkind JS: MAP kinases and control of nuclear events. Oncogene 26: 3240-3253, 2007.
3. McKay MM and Morrison DK: Integrating signals from RTKs to ERK/MAPK. Oncogene 26: 3113-3121, 2007.
4. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
5. Prowse CN, Hagopian JC, Cobb MH, Ahn NG and Lew J: Catalyric reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry 39: 6258-6266, 2000.
6. Marais R, Wynne J and Treisman R: The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73: 381-393, 1993.
7. Yang SH, Whitmarsh AJ, Davis RJ and Sharrocks AD: Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J 17: 1740-1749, 1998.
8. Brunner D, Oellers N, Szabad J, Biggs WH III, Ziipursky SL and Hafen E: Again-of-function in Drosophila MAP kinase activates multiple receptor tyrosine kinase signaling. Cell 76: 875-888, 1994.
9. Chu Y, Solski PA, Khosravi-Far R, Der CJ and Kelly K: The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271: 6497-6501, 1996.
10. Bott CM, Thorneycroft SG and Marshall CJ: The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action. FEBS Lett 352: 201-205, 1994.
11. Kim M, Lee JH, Koh H, et al: Inhibition of ERK-MAP kinase signaling by RSK during Drosophila development. EMBO J 25: 3056-3067, 2006.
12. Arvind R, Shimamoto H, Momose F, Amagasa T, Omura K and Tsuchida N: A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation. Int J Oncol 27: 1499-1504, 2005.
13. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761-771, 1988.
14. Ikeda M, Yokoyama M, Iritani A, Miura O, Katayama N, Yonemoto R, Fujinaga K, Yamaguchi N and Tsuchida N: Collaborative transformation with two oncogenes collaborating with v-src in primary cells and with an immortalization-positive SV40 mutated oncogene in established cells. In: Recent Progress of Life Science Technology in Japan. Academic Press, Tokyo, 1986.
15. Dignam JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
16. Zhang S, Fukushi M, Hashimoto S, et al: A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. Biochem Biophys Res Commun 297: 17-23, 2002.
17. Huang L, Gotoh N, Zhang S, Shibuya M, Yamamoto T and Tsuchida N: SNT-2 interacts with ERK2 and negatively regulates ERK2 signaling in response to EGF stimulation. Biochem Biophys Res Commun 324: 1011-1017, 2004.
18. Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N and Tsuchida N: Unique role of SNT-2/ FRS2/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. Oncogene 25: 6457-6466, 2006.
19. Brand AH and Perrimon N: Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401-415, 1993.
20. Spradling AC: P-element-mediated transformation. In: Drosophila: A Practical Approach. Roberts DB (ed). IRL Press, Oxford, 1986.
21. Robertson HM, Preston CR, Philips RW, Johnson-Schlitz DM, Benz WK and Engels WR: A stable genomic source of P-element transposase in Drosophila melanogaster. Genetics 118: 461-470, 1988.
22. Yamaguchi M, Hirose F, Inoue YH, Shiraki M, Hayashi Y, Nishi Y and Matsukage A: Ectopic expression of human p53 inhibits entry into S-phase and induces apoptosis in the Drosophila eye imaginal disc. Oncogene 18: 6767-6775, 1999.
23. Tanoue T, Adachi M, Moriguchi T and Nishida E: A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2: 110-116, 2000.
24. Whitehurst AW, Robinson FL, Moore MS and Cobb MH: The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J Biol Chem 279: 12840-12847, 2004.
25. Hoshino R, Chatani Y, Yamori T, et al: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
26. Mishima K, Inoue K and Hayashi Y: Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38: 468-474, 2002.
27. Schmidt CM, McKillop IH, Cahill PA and Sitzmann JV: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236: 54-58, 1997.
28. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, et al: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187, 1995.
29. Bang YJ, Kwon JH, Kang SH, Kim JW and Yang YC: Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun 250: 43-47, 1998.
30. Yazicioglu MN, Goad DL, Ranganathan A, Whitehurst AW, Goldsmith EJ and Cobb MH: Mutations in ERK2 binding sites affect nuclear entry. J Biol Chem 282: 28759-28767, 2007.
31. Kondoh K and Nishida E: Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773: 1227-1237, 2007.
32. Brondello JM, Pouyssegur J and McKenzie FR: Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286: 2514-2517, 1999.
33. Robinson FL, Whitehurst AW, Raman M and Cobb MH: Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1. J Biol Chem 277: 14844-14852, 2002.
34. Silverman E, Frödin M, Gammeltoft S and Maller JL: Activation of p90 Rsk1 is sufficient for differentiation of PC12 cells. Mol Cell Biol 24: 10573-10583, 2004.